Compare SOFI & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SOFI | VTRS |
|---|---|---|
| Founded | 2011 | 1961 |
| Country | United States | United States |
| Employees | N/A | 30000 |
| Industry | Diversified Financial Services | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.2B | 18.7B |
| IPO Year | 2020 | 2019 |
| Metric | SOFI | VTRS |
|---|---|---|
| Price | $17.09 | $17.01 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 16 | 4 |
| Target Price | ★ $24.43 | $13.50 |
| AVG Volume (30 Days) | ★ 82.7M | 9.1M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 3.21% |
| EPS Growth | ★ N/A | N/A |
| EPS | 0.12 | ★ 0.15 |
| Revenue | $619,353,000.00 | ★ $14,299,900,000.00 |
| Revenue This Year | $32.54 | $4.41 |
| Revenue Next Year | $21.82 | $1.96 |
| P/E Ratio | $147.17 | ★ $117.63 |
| Revenue Growth | ★ 23.10 | N/A |
| 52 Week Low | $14.92 | $8.63 |
| 52 Week High | $32.73 | $17.68 |
| Indicator | SOFI | VTRS |
|---|---|---|
| Relative Strength Index (RSI) | 45.53 | 56.13 |
| Support Level | $16.84 | $15.82 |
| Resistance Level | $19.18 | $17.17 |
| Average True Range (ATR) | 0.90 | 0.51 |
| MACD | -0.16 | 0.07 |
| Stochastic Oscillator | 19.11 | 62.32 |
SoFi is a financial-services company that was founded in 2011 and is based in San Francisco. Initially known for its student loan refinancing business, the company has expanded its product offerings to include personal loans, credit cards, mortgages, investment accounts, banking services, and financial planning. The company intends to be a one-stop shop for its clients' finances and operates solely through its mobile app and website. Through its acquisition of Galileo in 2020, the company also offers payment and account services for debit cards and digital banking.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.